To evaluate the prognostic impact of CXCR5 and LAG‐3 expression in CD8+ T cells on DLBCL patients, the post‐treatment 5‐year OS, and PFS rates were analyzed. Here, LAG3 is linked to diffuse large B-cell lymphoma.